Peptide-Drug Conjugates for Cancer
Peptide-Drug Conjugates
~96 PDCs in development
Approximately 96 peptide-drug conjugates are currently in preclinical or clinical development for cancer, with 6 in Phase 3 trials. Only Lutathera has maintained FDA approval.
Armstrong et al., J Pept Sci, 2025
Armstrong et al., J Pept Sci, 2025
View as imageCancer chemotherapy has a targeting problem. Cytotoxic drugs kill dividing cells, but they cannot distinguish cancer cells from healthy cells that also divide rapidly. The result: hair loss, nausea, immune suppression, organ damage. The field has spent decades trying to solve this by attaching toxic payloads to molecules that can find tumors and deliver drugs selectively. Antibody-drug conjugates (ADCs) solved part of this problem using large antibodies as targeting vehicles, producing blockbuster drugs like trastuzumab emtansine and enfortumab vedotin. But antibodies are massive (approximately 150 kDa), expensive to manufacture, limited in their ability to penetrate solid tumors, and sometimes immunogenic. Peptide-drug conjugates (PDCs) represent the next iteration: smaller targeting vehicles (typically 1-5 kDa) that penetrate tumors more efficiently, clear from non-target tissues faster, cost less to produce, and can be chemically synthesized with high reproducibility. One PDC, 177Lu-DOTATATE (Lutathera), has maintained FDA approval. Another, melphalan flufenamide (Pepaxto), was approved and then withdrawn. Approximately 96 more are in development. For how PDCs compare structurally and pharmacologically to their antibody-based predecessors, see How PDCs Compare to Antibody-Drug Conjugates: Smaller, Faster, Cheaper?. For the broader landscape of peptides that kill cancer cells through direct mechanisms, see Anticancer Peptides: How They Selectively Kill Tumor Cells.
Key Takeaways
- 177Lu-DOTATATE (Lutathera) reduced progression risk by 79% versus high-dose octreotide in the NETTER-1 Phase 3 trial, with estimated PFS of 40 months versus 8.4 months (Harris et al., Front Endocrinol, 2022)
- Melphalan flufenamide (Pepaxto) received FDA accelerated approval in 2021 for multiple myeloma but was withdrawn after the confirmatory OCEAN trial showed a survival disadvantage versus the control arm (Jessee et al., Ann Pharmacother, 2022)
- PDCs offer manufacturing advantages over ADCs: chemical synthesis versus biological production, lower molecular weight (1-5 kDa vs. 150 kDa), better tumor penetration, and faster renal clearance reducing prolonged systemic toxicity (Ma et al., Curr Med Chem, 2017)
- Alpha-emitting radiopeptides (actinium-225, lead-212) represent the next generation of peptide receptor radionuclide therapy, delivering higher linear energy transfer radiation over shorter path lengths to reduce damage to surrounding normal tissue (Bhimaniya et al., PET Clinics, 2024)
- RGD-based peptide conjugates targeting integrin receptors on tumor vasculature delivered doxorubicin and paclitaxel to glioma models with enhanced tumor accumulation and reduced systemic toxicity (Chen et al., ACS Appl Mater Interfaces, 2017)
- Somatostatin receptor-based PRRT has been tested with both agonist and antagonist peptides, with antagonists showing higher tumor uptake despite not triggering receptor internalization (Santo et al., Semin Nucl Med, 2024)
The Three Components of a Peptide-Drug Conjugate
Every PDC consists of three functional elements: a targeting peptide, a cytotoxic payload, and a linker connecting them. Each element determines a different aspect of the drug's behavior.
The Targeting Peptide
The peptide component provides tumor selectivity. It binds to receptors or antigens that are overexpressed on cancer cells relative to normal tissue. Ma et al.'s 2017 review in Current Medicinal Chemistry cataloged the major targeting strategies: somatostatin analogs binding somatostatin receptors (overexpressed in neuroendocrine tumors), RGD peptides binding integrin alpha-v-beta-3 (overexpressed on tumor vasculature), GnRH/LHRH analogs binding gonadotropin-releasing hormone receptors (overexpressed in breast and prostate cancers), bombesin analogs binding gastrin-releasing peptide receptors (overexpressed in prostate, breast, and pancreatic cancers), and substance P analogs binding neurokinin-1 receptors (overexpressed in gliomas).[1]
The peptide's receptor affinity determines how much drug reaches the tumor versus non-target tissues. Higher affinity means more selective accumulation, but the relationship is not linear. Peptides with extremely high receptor affinity can actually reduce tumor penetration by binding so tightly to surface receptors that they fail to diffuse deeper into the tumor mass, a phenomenon called the "binding site barrier." For a detailed examination of somatostatin-based targeting, see Somatostatin PDCs: Using Hormone Receptors as Drug Delivery Addresses.
The Cytotoxic Payload
The payload is the drug that kills the cancer cell once delivered. Payloads fall into three classes based on potency. Ultra-potent agents (auristatins, maytansinoids, duocarmycins) have subnanomolar cytotoxicity and require targeted delivery because free administration would cause unacceptable toxicity. Conventional chemotherapy agents (doxorubicin, paclitaxel, melphalan) benefit from tumor-selective delivery to reduce off-target effects. Radionuclides (lutetium-177, yttrium-90, actinium-225) deliver ionizing radiation directly to receptor-expressing tumor cells in peptide receptor radionuclide therapy (PRRT).
Xiang et al.'s 2018 study in the International Journal of Pharmaceutics demonstrated the payload delivery concept by conjugating doxorubicin to a human-derived cell-penetrating peptide.[2] The conjugate achieved improved anticancer efficacy compared to free doxorubicin, with reduced off-target toxicity. The CPP-doxorubicin conjugate penetrated tumor cells through a mechanism independent of surface receptor expression, expanding the potential target population beyond receptor-positive tumors.
The Linker
The linker connecting peptide to payload determines when and where the drug is released. This is not a passive structural element. Linker chemistry controls the entire pharmacokinetic profile of the conjugate. Cleavable linkers release the payload in response to specific conditions found in tumor tissue: low pH (acid-labile linkers), reducing environments (disulfide linkers), or tumor-associated enzymes (protease-cleavable linkers). Non-cleavable linkers rely on complete degradation of the conjugate inside the cell after internalization.
Costoplus et al.'s 2019 study in ACS Medicinal Chemistry Letters illustrated the impact of linker design by engineering peptide-cleavable self-immolative maytansinoid antibody-drug conjugates that provided improved bystander killing activity.[3] The peptide-cleavable linker released the payload selectively in the tumor microenvironment, where tumor-associated proteases were concentrated. The self-immolative spacer ensured that once the linker was cleaved, the active drug was released cleanly without residual linker fragments that could reduce potency. For a complete treatment of linker design principles, see PDC Linker Chemistry: How the Connection Determines the Release.
Why Peptides Instead of Antibodies?
ADCs have been commercially successful (14 FDA-approved as of 2025), but they carry structural limitations that PDCs can address.
Size and penetration. Antibodies are approximately 150 kDa. Tumor vasculature is leaky compared to normal tissue, but the interstitial pressure inside solid tumors is elevated, creating a barrier to macromolecule penetration. Peptides at 1-5 kDa diffuse through tumor tissue 10 to 100 times faster than antibodies, reaching cancer cells that are distant from blood vessels. Ma et al. noted that antibody applications remain somewhat limited in solid tumors precisely because of this penetration barrier.[1]
Clearance and toxicity. Antibodies have long circulating half-lives (days to weeks), which increases tumor exposure but also prolongs systemic toxicity. Peptides clear rapidly through renal filtration (half-lives of minutes to hours), reducing the duration of off-target effects. This rapid clearance can be a double-edged sword: it limits the time available for tumor accumulation, requiring either repeated dosing or chemical modifications (PEGylation, cyclization, D-amino acid substitution) to extend circulation.
Manufacturing. ADCs require biological production of the antibody component, followed by chemical conjugation to the payload. This process is expensive, batch-variable, and limited to specialized facilities. PDCs can be manufactured entirely through chemical synthesis, which is cheaper, more reproducible, and scalable. The heterogeneity of ADC preparations (variable drug-to-antibody ratios, inconsistent conjugation sites) contrasts with the defined, homogeneous products achievable through solid-phase peptide synthesis.
Immunogenicity. Even humanized antibodies can trigger anti-drug antibody responses that reduce efficacy over repeated dosing cycles. Peptides, being much smaller and typically non-immunogenic, rarely provoke such responses.
The Approved PDC: Lutathera and PRRT
177Lu-DOTATATE (Lutathera) is the only PDC that has maintained FDA approval for cancer treatment. It consists of the somatostatin analog octreotide (the targeting peptide) chelated to lutetium-177 (the radioactive payload) via the DOTA chelator (the linker). When injected intravenously, it binds to somatostatin receptors (particularly SSTR2) that are overexpressed on neuroendocrine tumor cells, delivering targeted beta radiation.
Harris et al.'s 2022 review in Frontiers in Endocrinology traced the evolution of PRRT from its origins in the 1990s through the pivotal NETTER-1 Phase 3 trial.[4] That trial, published in the New England Journal of Medicine in 2017, randomized patients with advanced midgut neuroendocrine tumors to 177Lu-DOTATATE plus standard-dose octreotide versus high-dose octreotide alone. The results were unambiguous: 177Lu-DOTATATE reduced progression risk by 79%, with estimated progression-free survival of 40 months versus 8.4 months for the control arm. Final overall survival data showed a median of 48.0 months versus 36.3 months, an 11.7-month difference that was clinically meaningful though not statistically significant due to crossover from the control arm. Early somatostatin-based radiopeptides used indium-111 (primarily a gamma emitter with limited therapeutic effect) before shifting to yttrium-90 (a pure beta emitter with longer tissue penetration) and then to lutetium-177 (a beta emitter with shorter range, reducing kidney and bone marrow toxicity). Each generational shift improved the therapeutic ratio between tumor kill and normal tissue damage.
Fosse et al.'s 2024 randomized study in the Journal of Nuclear Medicine compared PRRT directly with everolimus (a targeted oral therapy) in metastatic neuroendocrine tumors, providing head-to-head evidence for treatment selection.[5] For the emerging alpha-emitter approach that may represent the next step beyond Lutathera, see Alpha-Emitter PRRT: The Next Generation of Radioactive Peptides.
The Withdrawn PDC: Pepaxto's Cautionary Story
Melphalan flufenamide (melflufen, marketed as Pepaxto) was the first non-radioactive PDC to receive FDA approval for cancer. Its mechanism was distinct from receptor-targeting PDCs: rather than using a receptor-binding peptide for tumor delivery, it used a peptide substrate for aminopeptidases, enzymes that are overexpressed in multiple myeloma cells. Once inside the cell, aminopeptidases cleave the peptide bond, releasing the active alkylating agent melphalan at high intracellular concentrations.
Jessee et al.'s 2022 review in the Annals of Pharmacotherapy documented the clinical trajectory.[6] The Phase 2 HORIZON trial showed response rates sufficient for accelerated FDA approval in February 2021. But the confirmatory Phase 3 OCEAN trial, comparing melflufen plus dexamethasone versus pomalidomide plus dexamethasone, delivered a contradictory result. While progression-free survival favored melflufen, overall survival favored the control arm. The FDA issued a partial clinical hold, and in October 2021, the company voluntarily withdrew the drug from the US market. It retains EMA and MHRA approval in Europe and the UK.
The Pepaxto story illustrates a recurring challenge in PDC development: demonstrating that tumor-targeted drug delivery translates into overall survival benefit. A PDC can successfully concentrate drug in tumor cells, but if the payload or the delivery mechanism creates unexpected toxicities, or if the drug simply is not potent enough to overcome resistance mechanisms, targeted delivery alone is insufficient.
Targeting Strategies: How PDCs Find Tumors
RGD Peptides and Integrin Targeting
Integrins, particularly alpha-v-beta-3, are overexpressed on tumor neovasculature and on many solid tumor cells. The tripeptide sequence arginine-glycine-aspartate (RGD) binds these integrins with high affinity, making it one of the most widely used tumor-targeting peptides.
Chen et al.'s 2017 study in ACS Applied Materials and Interfaces demonstrated dual-targeting for glioma by combining cyclic RGD (for integrin targeting on tumor vasculature) with Peptide-22 (for low-density lipoprotein receptor targeting on the blood-brain barrier) on liposomal drug carriers.[7] The dual-functionalized liposomes crossed the blood-brain barrier and accumulated in glioma tissue more efficiently than either single-targeting formulation. This study illustrates a broader principle in PDC design: combining multiple targeting peptides on a single delivery platform can overcome biological barriers that single-target approaches cannot. For the specific pharmacology of RGD-based conjugates, see RGD-Based Peptide-Drug Conjugates: Delivering Chemo to Tumors.
Neuropeptide Receptor Targeting
Tumors of neuroendocrine origin overexpress receptors for multiple neuropeptides beyond somatostatin. Majkowska-Pilip et al.'s 2018 study explored neurokinin-1 (NK-1) receptor targeting for glioblastoma treatment.[8] The NK-1 receptor, which normally binds the neuropeptide substance P, is overexpressed in glioblastoma cells. By conjugating therapeutic payloads to substance P analogs, the researchers created tumor-selective delivery vehicles for one of the most treatment-resistant cancers. GnRH receptor targeting follows the same logic for hormone-responsive cancers. For how GnRH agonists are used in breast cancer therapy, the receptor biology that PDCs exploit is already validated clinically.
Next-Generation PRRT: Alpha Emitters and Antagonists
The success of Lutathera has spawned two major lines of innovation in peptide receptor radionuclide therapy.
Alpha-Emitting Radiopeptides
Beta-emitting radionuclides like lutetium-177 deposit energy over a relatively long path length (approximately 2 mm in tissue), which is effective for larger tumors but also irradiates surrounding normal tissue. Alpha emitters (actinium-225, bismuth-213, lead-212) deposit much higher energy over much shorter path lengths (50-100 micrometers), concentrating the radiation dose within a few cell diameters of the receptor-expressing target cell.
Bhimaniya et al.'s 2024 review in PET Clinics documented the early clinical experience with alpha-emitter PRRT.[9] Alpha particles produce dense ionization tracks that cause irreparable double-strand DNA breaks, making them effective even against radioresistant tumors. The short range limits damage to surrounding normal tissue, potentially improving the therapeutic ratio compared to beta emitters. Clinical data remain early-phase, but the theoretical advantages are driving active development.
Somatostatin Antagonists
A counterintuitive finding has reshaped PRRT research: somatostatin receptor antagonists, which bind the receptor without triggering internalization, actually achieve higher tumor uptake than agonists that are internalized. Santo et al.'s 2024 review in Seminars in Nuclear Medicine analyzed this paradox.[10] Antagonists appear to bind a larger number of receptor conformations, including both active and inactive states, effectively increasing the number of available binding sites on each tumor cell. For imaging and therapy, more binding sites mean more radiopeptide delivered per cell, even without internalization. Clinical trials comparing antagonist-based and agonist-based PRRT are underway.
The Pipeline: What Is Coming
Beyond Lutathera, the PDC pipeline spans multiple targeting strategies and payload types. CBX-12, a 26-amino acid conjugate developed by Cybrexa Therapeutics, uses a pH-activated mechanism: the peptide is designed to insert into cell membranes selectively at the lower pH found in tumor microenvironments, delivering its exatecan payload without requiring receptor-mediated targeting. Phase 1 enrollment completed in September 2024.
Avacta's pre|CISION platform takes yet another approach: using fibroblast activation protein (FAP) as the activation trigger. FAP is a protease overexpressed on cancer-associated fibroblasts in the tumor stroma. AVA6000, a FAP-activated doxorubicin prodrug, showed a median 100-fold concentration difference between tumors and blood in Phase 1 biopsy data. AVA6103, a FAP-activated exatecan conjugate, is expected to enter clinical trials in early 2026.
The diversity of these approaches reflects the field's central insight: there is no single best way to target a tumor. Different cancers express different surface markers, and the optimal PDC for each indication will depend on which receptors, enzymes, or microenvironmental conditions can be exploited for selective delivery.
Challenges That Remain
Several technical barriers continue to limit PDC clinical translation.
Rapid clearance. The same small size that gives PDCs better tumor penetration also means rapid renal clearance. A peptide that clears from the bloodstream in minutes has limited time to accumulate in tumor tissue. Strategies to extend circulation (PEGylation, albumin binding, depot formulations) can help, but each modification adds complexity and may reduce receptor affinity or tissue penetration.
Kidney toxicity. Small peptides are filtered and reabsorbed by the kidneys. For radiopeptide conjugates, this means the kidney receives significant radiation dose. Lutetium-177 PRRT requires co-infusion of amino acids to competitively inhibit renal peptide reabsorption. Alpha-emitter PRRT, with its higher energy per particle, may pose greater renal risk despite its shorter tissue range. Long-term nephrotoxicity data from Lutathera show manageable but real kidney effects in a subset of patients.
Payload release timing. A linker that is too stable fails to release the payload at the tumor site. A linker that is too labile releases the payload in circulation before reaching the tumor. Achieving the right balance requires extensive optimization for each specific peptide-payload combination, and what works in mouse models does not always translate to human pharmacokinetics. For a complete exploration of this design challenge, see PDC Linker Chemistry: How the Connection Determines the Release.
Heterogeneous receptor expression. Tumors are not uniform. Receptor expression varies between patients, between metastases in the same patient, and between regions within a single tumor. A PDC that targets somatostatin receptors will not reach tumor cells that have lost SSTR2 expression. Combination strategies, using multiple targeting peptides or combining PDCs with conventional therapy, may be necessary to address this heterogeneity.
Where the Evidence Stands
PDCs have proven the concept that small peptide-based targeting vehicles can deliver cytotoxic payloads selectively to tumors. Lutathera's NETTER-1 data provide Level 1 evidence for PRRT in neuroendocrine tumors. The broader PDC landscape beyond PRRT remains early-stage, with most programs in Phase 1 or 2. Pepaxto's withdrawal demonstrates that tumor-selective delivery does not automatically translate into survival benefit.
The structural advantages of PDCs over ADCs (smaller size, better penetration, chemical synthesis, lower immunogenicity) are well-established in preclinical comparisons. Whether these translate into consistently superior clinical outcomes is the open question that only ongoing trials can answer. The field's trajectory is clear: approximately 96 PDCs in development, 6 in Phase 3, and a growing understanding of which targeting strategies, linker chemistries, and payload classes perform best for which tumor types.
The Bottom Line
Peptide-drug conjugates use short targeting peptides to deliver cytotoxic payloads selectively to tumor cells. One PDC, Lutathera (177Lu-DOTATATE), has maintained FDA approval based on a 79% reduction in progression risk for neuroendocrine tumors. Another, Pepaxto (melphalan flufenamide), was approved and withdrawn after survival data favored the control arm. Approximately 96 PDCs are in development across multiple targeting strategies including somatostatin receptor targeting, RGD-integrin targeting, GnRH receptor targeting, and pH/enzyme-activated release. PDCs offer structural advantages over antibody-drug conjugates in tumor penetration, manufacturing cost, and immunogenicity, but translating these advantages into consistent clinical benefit remains an ongoing challenge.